Expert consensus on standards for multiple sclerosis care: results from a modified Delphi process

Helmut Butzkueven,¹ Jeremy Hobart,² Amy Bowen,³ Lucy Eberhard,⁴ George Pepper⁵ and Gavin Giovannoni,⁶ on behalf of the MS Brain Health Delphi Consensus Panel

¹Alfred Health and Eastern Health, Monash University, Melbourne, Australia; ²Plymouth University Peninsula Schools of Medicine and Dentistry, Plymouth, UK; ³NHS RightCare, London, UK; ⁴PharmaGenesis London, London, UK; ⁵Shift.ms, Leeds, UK; ⁶Queen Mary University London, Blizard Institute, Barts and the London School of Medicine and Dentistry, London, UK

Background

- The need for prompt diagnosis and early treatment of multiple sclerosis (MS) was highlighted by the widely endorsed policy report Brain health: time matters in multiple sclerosis.¹
- The current study aimed to define international standards for the timing of key steps in the MS care pathway.
- These standards will inform the content of tools to help MS services strive for the highest level of care.

Methods

- The Delphi process is a structured communication technique for gaining consensus among experts.
- Here, the Delphi process was modified to include both a core Delphi Consensus Panel and an additional Reviewing Group (Figure 1).




Figure 1. Modified Delphi process flow chart.

Participants


- Four Chairs directed the process; they represented neurology, patient-reported outcomes, nursing/policy and the patient perspective.
- In total, 39 MS neurologists from 26 countries were invited to participate in the **Delphi Consensus Panel** (Figure 1); 29 agreed to participate. All were currently based in an MS clinic and were spending at least half of their clinical time seeing patients with MS.
 - Panel members were required to take part in each round to remain in the process.
 - Responses were collected via online surveys, and participants remained anonymous to analysts and Chairs throughout.
- Thirty-nine MS nurses, people with MS and allied healthcare professionals were invited to participate in the **Reviewing Group**; 31 agreed to participate (**Figure 1**).

Consensus thresholds

The predefined thresholds for consensus were at least 75% agreement and at least 66% participation compared with round 1.

Disclosures

H Butzkueven has received consulting fees from Biogen, Genzyme, Merck, Novartis, Oxford Health Policy Forum and Oxford PharmaGenesis; and grant/research support to attend meetings or research support from Acorda, Asubio, Bayer Schering, Biogen Idec, F. Hoffmann-La Roche, Genzyme, Merck Serono, Novartis, Oxford Health Policy Forum, Oxford PharmaGenesis and Teva. A Bowen has received consulting fees from AbbVie, Atara Biotherapeutics, Almirall, Biogen, Celgene, GlaxoSmithKline, MedDay Pharmaceuticals, Merck and Company (US), Merck Group (Europe), Novartis, Oxford Health Policy Forum, Oxford Pharmaceutical Industries Ltd and UCB; and grant/research support from Biogen, Sanofi Genzyme and Takeda. Support for the preparation of this poster and for other MS Brain Health activities and materials has been provided by Oxford PharmaGenesis and Oxford, UK, funded by grants from Actelion, Celgene and Sanofi Genzyme and by educational grants from Biogen, F. Hoffmann-La Roche and Merck KGaA, all of whom had no influence on the content



consensus statement.

Standard	Defi
Core	This tear syste
Achievable	This refle
Aspirational	This whe shou

- asked to vote again.

from round 4 where consensus was not reached and were

Those who did not agree with the statements were asked to give reasons in a free-text box.

Figure 3. 'Achievable' standards related to re gained at least 75% agreement from the Delp DMT, disease-modifying therapy; MRI, magnetic resonance imaging



onsens	sus standards
toms	
•	e who reports symptoms that might be related to MS to a healthcare professional be referred to a neurologist within 10 days
	al MRI scan should be performed within 2 weeks of first referral to a neurologist nosis (if not performed earlier)
	team should complete a diagnostic workup for MS within 4 weeks of referral urologist
	urate diagnosis of (uncomplicated) MS should be made within 4 weeks of referral urologist
ostic workuj	D
	ults from a diagnostic workup for MS should be discussed within 10 days of tion, during an appointment with the patient
	ng MS diagnosis, patients should be offered an initial appointment of at minutes to discuss the implications of the diagnosis
	team should discuss the aims of treatment with each patient within 2 weeks iagnosis
	team should discuss the pros and cons of early treatment with a DMT with s within 3 weeks of diagnosis
	team should assess within 3 weeks of an MS diagnosis whether the patient ble for treatment with a suitable DMT
ible for DM1	
	should be offered to a patient with MS within 3 weeks of their becoming for one
art DMT	
	ent with a DMT should commence within 2 weeks of a patient with MS agreeing proach with their neurologist
	team should review at least once every 6 months whether each patient with o is not receiving a DMT is eligible for one, based on applicable guidelines
IS	
	team should perform a follow-up clinical evaluation of each patient at least once months
	team should review with each patient at least once every 6 months the aims of their ent for MS
	team should review with each patient at least once every 6 months their t ly prescribed DMT and consider alternatives if appropriate
r 🗕 All patie	ents with MS should be offered an MRI scan at least once every year
The MS	team should regularly enter patient data into an MS database
e to DMT	
•	ent's response to their current DMT is judged to be suboptimal, an appropriate, I tive DMT should be offered within 4 weeks
mptoms	
	ts with MS should report new or worsened symptoms to their MS team 7 days of experiencing these symptoms
orsened sym	ptoms
	team should respond within 2 days to a patient with MS reporting an acute ration of symptoms
	s with MS who experience an acute deterioration of symptoms should be seen relevant member of their MS team within 3 days of reporting these symptoms
	nosis, treatment decisions, monitoring and managing new symptoms, that us Panel in round 4.
• • • • • •	



Results

We summarize here the results from round 1 and round 4 and present a subset of the **achievable** standards where consensus was reached.

Participants

21/27 (78%) of the Delphi Consensus Panel completed round 4 (Figure 1), thus meeting the threshold for participation.

Defining a good standard of care (round 1)

- For all 21 principles, over 75% of the Panel (n = 27) agreed that the principle was an appropriate and accurate description of a good standard.
- Three statements gained 100% (27/27) agreement:
 - 'Early discussion with patient about the aims of treatment'
 - 'Evaluation of suitability/eligibility for treatment shortly after MS diagnosis'
- 'Regular review of the aims of treatment'.
- 'Timely offer of cognitive testing after MS diagnosis' gained the lowest agreement (78%; 21/27).
- Ten additional principles were included based on suggestions from both groups.

Consensus on key steps in the patient pathway (round 4)

- Consensus was reached on the majority of core (22/27), achievable (25/27) and aspirational (18/27) standards with timings and on four statements that did not include timings. Where consensus was not reached, the statements were taken forward to round 5; this is ongoing.
- Here, we present the standards on referral, diagnosis, treatment decisions, monitoring and managing new symptoms, which the Panel agreed should be achievable (Figure 3).

Next steps

- Additional consensus standards will be presented at a future date. These include:
- achievable standards related to symptom onset and a brain-healthy lifestyle
- core and aspirational consensus standards
- round 5 consensus standards.

Conclusions

- An international group of MS neurologists has agreed standards for the timing of key steps in the MS care pathway which relate to brain health.
- The standards presented here, and those to follow, will inform the development of an MS Brain Health quality improvement tool that will help established and developing MS clinics in different countries strive for the best possible standard of patient care.
- Alongside the clinical tool, the standards also provide the basis for a checklist that will help people with MS to bring about improvements in care.

Reference

Giovannoni G et al. Brain health: time matters in multiple sclerosis. *Mult Scler Relat Disord* 2016;9 Suppl 1:S5–S48.



